Cervical Cancer Diagnostic Tests Market Size to Exceed USD 12.19 Bn by 2032

The Cervical Cancer Diagnostic Tests Market, estimated at USD 7.95 Bn in 2025, is expected to exhibit a CAGR of 6.3% and reach USD 12.19 Bn by 2032.

The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.

The key market players are focused on adopting growth strategies such as partnership as well as acquisitions, which will drive the global cervical cancer diagnostic tests market during the forecast period. For instance, in February 2025, QIAGEN, a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, and INOVIO Pharmaceuticals, biotechnology company focused on the discovery, development, and commercialization of synthetic DNA (deoxyribonucleic acid) products for treating cancers and infectious diseases, announced an extension of its partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO’s therapies.

Global Cervical Cancer Diagnostic Tests Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.

COVID-19 had a negative impact on global cervical cancer diagnostic tests market. For instance, in April 2025, according to an article published in the Journal of Labs for Rent in Basel, cervical cancer tests performed using Pap smears, HPV testing, and colposcopies, as well as treatment volumes decreased significantly during the first 24 months of the COVID-19 pandemic compared with the pre-pandemic period. Consistent with the drop in cervical cancer investigation, each month between March and December 2025 saw an average of 49 percent fewer high-grade cytological abnormalities diagnosed. Although cervical screening, colposcopy, and treatment volumes had begun to rebound in area of study by January 2025.

Global Cervical Cancer Diagnostic Tests Market: Key Developments

In November 2025, Hologic, Inc., an innovative medical technology company, announced that its new Genius Digital Diagnostics System is now commercially available in Europe. The Genius Digital Diagnostics System is the next generation of cervical cancer screening that combines deep learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells in women. It was developed to provide actionable insights, and improve workflow and lab efficiency, all with one goal in mind– to eradicate cervical cancer.

In August 2025, oncgnostics GmbH Jena Germany, a company working on molecular diagnostics announced the availability of the cervical cancer screening test GynTect to physicians and patients in China. The product is the first approved methylation test for triage of (Human Papillomavirus) HPV-positive cases in China.

In August 2025, Sunway Medical Centre, a private clinics that provides a wide range of health screenings, medical treatments and services and United Imaging Healthcare (UIH), a global medical device manufacturer, developer and supplier are collaborating to optimize molecular imaging protocols using artificial intelligence (AI) modelled reconstruction for cancer diagnosis. With this partnership, Sunway Medical Centre will be the first hospital in Southeast Asia to acquire UIH’s state-of-the-art digital PET/CT system, the uMI780. The ultra-fast, high resolution digital PET/CT transforms traditional imaging by offering whole body coverage with the widest 30cm digital axial field of view.

In October 2025, The University of Texas MD Anderson Cancer Center, a comprehensive cancer center in U.S., and World Health Organization (WHO), announced a formal agreement to establish a new international collaboration concentrated on reducing the global burden of women’s cancers. The agreement builds on years of collaboration between the two institutions to further promote their shared efforts in advancing global cancer initiatives in women’s cancers, including breast and cervical cancers.

Browse 34 Market Data Tables and 26 Figures spread through 220 Pages and in-depth TOC on “Global Cervical Cancer Diagnostic Tests Market”- Forecast to 2032, Global Cervical Cancer Diagnostic Tests Market, By Test Type (Pap Smear Test, Colposcopy Test, Endocervical Curettage Test, and HPV Test), By Age Group (Age 20–40 and Age Above 40), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/cervical-cancer-diagnostic-tests-market-3994

Key Takeaways of the Global Cervical Cancer Diagnostic Tests Market:

• The global cervical cancer diagnostic tests market is expected to exhibit a CAGR of 6.3% during the forecast period. The research and development in the treatment and diagnosis offers lucrative growth opportunities to the key players such as product launch. For instance, in December 2025, Regeneron Pharmaceuticals, Inc., a biotechnology company announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Libtayo (cemiplimab) as monotherapy to treat patients with advanced or recurrent cervical cancer whose disease progressed after chemotherapy
• Among age group, the age above 40 segment is expected to growth in the global cervical cancer diagnostic tests market over the forecast period, the number of people who have had several partners has increased and long-lasting infection with certain types of human papillomavirus (HPV). For instance, on January 12 2025, according to the American Cancer Society, estimated that there will be 13,960 new instances of invasive cervical cancer diagnosed in the U.S. in 2025 and 4,310 women will pass away from the disease.
• Among Test type, the HPV test segment is expected to register highest CAGR during the forecast period owing to the presence of Human Papillomavirus (HPV) infection and availability of homes based sample collection kits of HPV test. For instance, on January 04 2025, Virax Biolabs, an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced the distribution of HPV test kits with shipments anticipated in Q1 of 2025 to markets accepting the CE (Conformité Européenne) mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent.
• Major players operating in the global cervical cancer diagnostic tests market include Guided Therapeutics, Inc., Abbott, Beckman Coulter, Inc., BD (Becton, Dickinson and Company), F. Hoffmann-La Roche Ltd, Bio Farma, Hologic, Inc., Oncgnostics GmbH, AstraZeneca, MobileODT, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., DYSIS Medical Inc., The Cooper Companies Inc., Danaher, Quest Diagnostics, Arbor Vita Corporation, and Zilico.